Alcon Inc. is a global eye care company operating through two main business segments: Surgical and Vision Care. The Surgical segment provides implantables, consumables, and equipment for cataract, vitreoretinal, refractive, and glaucoma surgeries, featuring products such as AcrySof IQ, PanOptix, Vivity, and the CENTURION Vision System. The Vision Care segment offers daily disposable, reusable, and color-enhancing contact lenses, including DAILIES TOTAL1, PRECISION1, and AIR OPTIX, alongside ocular health products like Systane, Pataday, and Opti-Free solutions. Alcon serves ophthalmic surgeons, optometrists, and consumers worldwide. The company was founded in 1945, formerly operated as a division of Novartis, and became a standalone entity in 2019. Recent acquisitions include LumiThera, Cylite, Aurion Biotech, and BELKIN Vision.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage alcon.com
Sector Healthcare IR page investor.alcon.com/home/default.aspx
Tags
ophthalmic surgery, contact lenses, intraocular lenses, dry eye treatment, glaucoma, vitreoretinal surgery, refractive surgery, lens care, ocular allergies, medical devices, AcrySof IQ, PanOptix, Vivity, CENTURION Vision System, DAILIES TOTAL1, PRECISION1, AIR OPTIX, Systane, Pataday, Opti-Free, LumiThera, Cylite, Aurion Biotech, BELKIN Vision, TOTAL30, PRECISION7, CLAREON, ARGOS Biometer, NGENUITY 3D Visualization System, LuxOR Revalia, ACTIVE SENTRY, HYPERVIT, FINESSE REFLEX, Systane iLux, MARLO, Fidelis VR, EYSUVIS, INVELTYS, ROCKLATAN, RHOPRESSA, Hydrus Microstent, Voyager Direct Selective Laser Trabeculoplasty, WaveLight, LenSx Lasers, Ivantis, Aerie Pharmaceuticals, Kala Pharmaceuticals
Press page —

Metrics

Valuation  
Market cap $ 31.3B
Market cap (USD) $ 31.3B
P/E 49.43
PEG 1.15
P/BV 1.45
P/S 2.88
P/OCF 13.55
P/FCF 17.99
Dividend yield —
Turnover / mcap —
Returns  
ROE 4.5%
ROI 3.7%
ROIC 4.4%
Profit margin 9.4%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 43.0%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity 19.2%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 38
Quality score 11.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2010 FY 2009
Revenue 10.401B 9.911B 9.455B 8.717B 8.291B 6.833B 7.508B 7.153B 7.179B 6.499B
Net profit 980M 1.018B 974M 335M 376M -531M -656M -227M 2.21B 2.007B
Free cash flow 1.728B 1.604B 730M 581M 645M 344M 367M 616M 2.066B 2.074B

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2010 FY 2009
Share price 78.81 84.89 78.12 68.55 87.12 65.98 56.57 — — —
Price performance 12m -0.07 0.09 0.14 -0.21 0.32 0.17 — — — —

Filed figures

Figure Dec 2010 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 1.48B — — — — — — — — —
↳ YoY growth +10.2%
Borrowings, current (USD) 399M — — — — — — — — —
Borrowings, non-current (USD) 0.00 — — — — — — — — —
Cash and deposits (USD) 2.53B — — — — — — — — —
Intangible assets (USD) 953M — — — — — — — — —
Net debt (borrowings + leases - cash) (USD) -2.13B — — — — — — — — —
Cash flow detail
Operating cash flow (USD) 2.38B — — — — — — — — —
Purchases of property, plant and equipment (USD) -309M — — — — — — — — —
Purchases of intangible assets (USD) -137M — — — — — — — — —
Change in receivables (cash effect) (USD) 129M — — — — — — — — —
Change in inventories (cash effect) (USD) 54M — — — — — — — — —
Change in payables (cash effect) (USD) 49M — — — — — — — — —
Dividends paid (cash effect) (USD) -1.04B — — — — — — — — —
Share buybacks (cash effect) (USD) -33M — — — — — — — — —
Interest paid (cash effect) (USD) -9M — — — — — — — — —
Income taxes paid (cash effect) (USD) -284M — — — — — — — — —
Share-based compensation (USD) 78M — — — — — — — — —
Operating cash flow before change in receivables (USD) 2.25B — — — — — — — — —
Free cash flow (OCF - PPE - intangibles) (USD) 1.93B — — — — — — — — —
Income detail
Research and development expense (USD) 747M 584M 587M 656M 673M 842M 702M 828M 876M 990M
↳ 5y CAGR +3.7% +7.1% +6.0% +8.0%
Provision for credit losses (USD) 19M — — — — — — — — —
Credit cost ratio (credit losses / average receivables) (%) 1.3% — — — — — — — — —
Reported Mar 18, 2011 Feb 25, 2020 Feb 25, 2020 Feb 25, 2020 Feb 23, 2021 Feb 15, 2022 Feb 27, 2023 Feb 27, 2024 Feb 25, 2025 Feb 24, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

•Third-quarter 2026 sales of $2.7 billion, +5%, +5% constant currency1 (cc), vs. third-quarter 2025

•Year-to-date 2026 sales of $8.2 billion, +7%, +6% cc, vs. the same period last year

•Third quarter 2026 diluted EPS of $0.54, +13%, +14% cc; core diluted EPS2 of $0.91, +15%, +15% cc, vs. third-quarter 2025

•Returned $748 million to shareholders on a year-to-date basis

•Recently announced the acquisition of Neurotech Pharmaceuticals, Inc. ("Neurotech"), strengthening our portfolio of products in retinal disease

Ad Hoc Announcement Pursuant to Art. 53 LR

Geneva, November 10, 2026 - Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and nine month periods ending September 30, 2026. For the third quarter of 2026, sales were $2.7 billion, up 5% on a reported and constant currency basis1, as compared to the same quarter of the previous year. Alcon reported diluted earnings per share of $0.54 and core diluted earnings per share2 of $0.91 in the third quarter of 2026.

10/20/2026

  • Expands Alcon’s retina portfolio with ENCELTO, an encapsulated cell therapy intended for surgical implantation in the eye for patients with MacTel Type 2, a rare retinal disease
  • Alcon's established presence and expertise in surgical retina is expected to accelerate commercialization and patient access
  • Broadens Alcon’s offering in retinal disease

GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has acquired Neurotech Pharmaceuticals, Inc., a company focused on developing innovative cell therapies for chronic and neurodegenerative eye diseases.

This acquisition expands Alcon's retina portfolio with ENCELTO™ (revakinagene taroretcel-lwey), the first and only U.S. FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2 (MacTel), a rare, progressive retinal disease that leads to irreversible central vision loss that has historically had no approved treatment options. ENCELTO is an encapsulated cell therapy that is intended for surgical intravitreal implantation. The FDA granted ENCELTO priority review status and Orphan Drug designation and approved ENCELTO under a Biologics License Application (BLA) in March 2025. It currently is available in the U.S. only.

"Neurotech's innovative platform sits at the intersection of cell therapy, pharmaceuticals, and surgery, making it a highly complementary addition to our current capabilities and advancing our vision for the future of retinal disease treatment,” said David Endicott, Chief Executive Officer of Alcon. "By combining Neurotech’s groundbreaking science and established commercial footprint with Alcon's global reach and clinical expertise, we can help bring this innovation to more patients whose vision is threatened by MacTel."

It is estimated that there are approximately 25,000 diagnosed MacTel patients in the U.S. with 2,000-3,000 patients newly diagnosed annually.1-3,† Until ENCELTO, there have been no FDA-approved treatments for MacTel patients. ENCELTO continuously releases a protein called recombinant human ciliary neurotrophic factor (rhCNTF) that can directly reach the retina, the light-sensitive part of the eye. CNTF helps protect certain cells in the retina, supporting their health and reducing the loss of light-sensing cells known as photoreceptors.

“ENCELTO addresses a significant unmet need for MacTel patients,” said Dan Miller, MD, PhD, Distinguished Fellow, Research & Development, Alcon. “Alcon's presence in surgical retina combined with its dedication to innovation make them the ideal partner to broaden access to this important therapy.”

“This milestone significantly advances Neurotech’s mission to bring ENCELTO to patients suffering from this debilitating disease,“ said Richard Small, Chief Executive Officer of Neurotech Pharmaceuticals, Inc. “Alcon’s global scale, commercial capabilities and scientific expertise will expand and facilitate patient access to ENCELTO, and I’m grateful to the entire Neurotech team, as well as the physicians, investigators, patients, and advocates within the MacTel community whose dedication has made this achievement possible.”

As part of the acquisition, Alcon paid $550 million to acquire Neurotech Pharmaceuticals, Inc. Alcon may be required to make additional contingent payments, including upon the achievement of commercial milestones.

Alcon expects the transaction to be modestly accretive to net sales growth and slightly dilutive to core diluted eps in 2027, and accretive thereafter.

Goldman Sachs & Co, served as financial advisor to Alcon and Gibson, Dunn & Crutcher LLP served as legal advisor to Alcon. J.P. Morgan Securities, LLC. served as lead financial advisor to Neurotech, and Cravath Swaine & Moore LLP served as lead legal advisor to Neurotech. Other advisors to Neurotech included Rothschild & Co, Ropes & Gray LLP, Fenwick & West LLP and Elrifi Law PLLC.

Cautionary Note Regarding Forward-Looking Statements

This document contains, and our officers and representatives may from time to time make, certain “forward-looking statements” within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “anticipate,” “intend,” “commitment,” “look forward,” “maintain,” “plan,” “goal,” “seek,” “target,” “assume,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding the transaction and the expected timing, impacts and benefits thereof.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict such as: (i) the failure to realize the anticipated benefits of the acquisition, including our ability to accelerate commercialization and patient access; and (ii) there may be liabilities related to the acquisition that are not known, probably or estimable at this time or unexpected costs, charges or expenses.

Additional factors are discussed in our filings with the United States Securities and Exchange Commission, including our Form 20-F. Should one or more of these uncertainties or risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated. Therefore, you should not rely on any of these forward-looking statements. Forward-looking statements in this document speak only as of the date of its filing, and we assume no obligation to update forward-looking statements as a result of new information, future events or otherwise.

About Alcon

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries and territories each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com .

About Neurotech Pharmaceuticals, Inc.

Neurotech Pharmaceuticals, Inc. is a private biotech company focused on developing transformative therapies for chronic eye diseases. The core platform technology, Encapsulated Cell Therapy (ECT) is a first in class, drug delivery platform designed to slow the progression of MacTel and other chronic eye diseases. Learn more at https://www.neurotechpharmaceuticals.com .

About Macular Telangiectasia Type 2 (MacTel)

Macular Telangiectasia Type 2 (MacTel), or idiopathic macular telangiectasia type 2, is a bilateral, neurodegenerative disease in adults with characteristic localized retinal degeneration, a group of diseases that cause the gradual loss of cells in the retina, resulting in vision loss and secondary alterations of the retinal vasculature, the network of blood vessels that supplies oxygen and nutrients to the retina.4

About Encapsulated Cell Therapy (ECT)

Neurotech’s ECT platform is a cell-based gene therapy delivery system designed to provide long-term, sustained delivery of therapeutic proteins for the treatment of chronic eye diseases. This versatile platform consists of a small, semi-permeable capsule containing proprietary allogeneic retinal pigment epithelium (RPE) cells genetically engineered to produce specific therapeutic proteins for targeted disease treatment.

Indications and Usage

ENCELTO is an allogeneic encapsulated cell-based gene therapy indicated for the treatment of adults with idiopathic macular telangiectasia type 2 (MacTel).

IMPORTANT SAFETY INFORMATION

ENCELTO is inserted into the eye as an outpatient surgical procedure performed by an eye surgeon experienced in vitreoretinal surgery. If removal of ENCELTO is necessary, the removal surgery must also be done by an eye surgeon experienced in vitreoretinal surgery in an operating room as an outpatient surgery.

Please be advised that ENCELTO and the surgical insertion has related risks such as, but not limited to, endophthalmitis (eye infection), retinal tear and detachment (retina tears and potentially separates from the eye wall resulting in vision loss) vitreous hemorrhage, implant, extrusion, suture-related issues, temporary or permanent loss of vision, accelerated cataract formation and delayed dark adaptation

Patients may report side effects to the Food and Drug Administration (FDA) at 1-800-FDA-1088.

Please see full Prescribing Information and Patient Information for ENCELTO.

†Calculation performed using the US 2020 population (331,449,281).

Reference:

1. Claims dataset analysis (2018-24). Data as of 2023 - Alcon data on file.
2. Starr MR, et al. Ophthalmic Surg Lasers Imaging Retina. 2020;51(5): S35-S42.
3. United States Census Bureau. “Populations and People.” Accessed Jan 2024.
4. Charbel Issa P, Gillies MC, Chew EY, Heeren TFC, Bird AC, Peto T, Holz FG, Scholl HPN (2013) Macular Telangiectasia Type 2.

**Connect with us on
**Facebook

Instagram

Investor Relations
Daniel Cravens/ Richard Bourne
+ 41 589 112 110 (Geneva)
+ 1 817 615 2789 (Fort Worth)
[email protected]

Media Relations
Steven Smith
+ 41 589 112 111 (Geneva)
+ 1 817 551 8057 (Fort Worth)
[email protected]

Source: Alcon Inc. Investors

Multimedia Files:

View All News

10/16/2026

  • Download (opens in new window)

  • One drop works to significantly reduce redness, with results lasting up to 12 hours1

  • Lasts up to 50% longer than Lumify1-2,*

  • Expands Alcon's portfolio of consumer eye care solutions and will be available in major retailers nationwide and online in the coming months

GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that the U.S. Food and Drug Administration (FDA) has approved BRYTLY® Redness Reliever Eye Drops. With one drop, BRYTLY works in just one minute to significantly reduce redness and delivers up to 12 hours of whiter, brighter-looking eyes.1 Additionally, BRYTLY lasts up to 50% longer than Lumify.1-2,* The approval brings a differentiated new option to the over the counter (OTC) redness-relief category and expands Alcon’s portfolio of trusted consumer eye care products.

FDA Approves Alcon’s BRYTLY Redness Reliever Eye Drops

FDA Approves Alcon’s BRYTLY Redness Reliever Eye Drops

Beauty and wellness routines are increasingly converging, with consumers looking for products that combine visible results, clinical validation and everyday convenience. Research has also found that visible eye redness can influence perceptions of healthiness and attractiveness, creating new relevance for the eyes as part of an overall appearance and wellness routine.3 BRYTLY brings a clinically proven option to this evolving space, by reducing redness and helping eyes look whiter and brighter with results that can last throughout the day, up to 12 hours.

“Consumers invest in products that help them look and feel their best, and the appearance of their eyes can be an important part of that,” said Jonathan Balch, General Manager, Ocular Health & Pharmaceuticals, Alcon. “This FDA approval marks an exciting milestone for Alcon. With BRYTLY, we’re bringing Alcon’s trusted eye care expertise to consumers who want to reduce eye redness and want their eyes to look whiter and brighter. BRYTLY is designed to deliver simple, long-lasting redness reduction that can help consumers feel confident in how their eyes look throughout the day.”

BRYTLY contains no bleaches or dyes and is clinically proven to be safe and effective when used as directed.1 Studies also demonstrated a low risk of redness rebound and tachyphylaxis when used as directed.4-5

“When patients ask about eye whiteners, they want a product they can trust to work effectively and fit into their day,” said Selina McGee**, founder and chief optometrist of Bespoke Vision in Edmond, Oklahoma. “BRYTLY gives Eye Care Professionals a clinically proven option to recommend, with demonstrated safety and efficacy and long-lasting redness reduction from a single drop.”

BRYTLY is expected to be available at major retailers nationwide and online in the coming months, and in additional markets in the future.

About Alcon

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries and territories each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com .

_*Based on label claim, BRYTLY up to 12 hours / Lumify up to 8 hours.
_**Paid Alcon consultant.

References

  1. Alcon- BRYTLY Label, 2026.
  2. BAUSCH + LOMB Lumify Label. DailyMed. Published 2025. Accessed February 19, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=022de945-0b26-40ae-8e88-d3fe2464d106 .
  3. Provine RR, Cabrera MO, Nave-Blodgett J. Red, yellow, and super-white sclera: uniquely human cues for healthiness, attractiveness, and age. Human Nature. 2013;24:126–136. doi:10.1007/s12110-013-9168-x.
  4. Alcon data on file, 2025; REF-27135.
  5. Alcon data on file, 2025; REF-27136.

Connect with us on

Facebook

LinkedIn

Investor Relations
Dan Cravens, Richard Bourne
+ 41 589 112 110 (Geneva)
+ 1 817 615 2789 (Fort Worth)
[email protected]

Media Relations
Steven Smith
+ 41 589 112 111 (Geneva)
+ 1 817 551 8057 (Fort Worth)
[email protected]

Source: Alcon Inc. Investors

Multimedia Files:

View All News

Prompts

Alcon Inc. (ticker ALC), listed in United States.

ETFs Holding Alcon Inc.

ETF Weight in ETF Shares Market value As of
EQTY 2.98% 616,566 $ 42.506M Jul 31, 2026
RUNN 1.84% 105,996 $ 7.638M Aug 31, 2026
TLCI 1.72% 28,220 $ 1.907M Jun 30, 2026
CORO 0.17% 379,073 $ 28.07M Nov 16, 2026
DFIV 0.16% 490,935 $ 35.264M Nov 12, 2026
ENHI 0.12% 332 $ 24.585K Nov 16, 2026
DFAI 0.11% 276,485 $ 19.86M Nov 12, 2026
DFIC 0.09% 201,151 $ 14.449M Nov 12, 2026
DXIV 0.08% 2,840 $ 203.997K Nov 12, 2026
DFAX 0.07% 112,823 $ 8.104M Nov 12, 2026
DFSI 0.07% 10,784 $ 774.615K Nov 12, 2026
IALT short -0.06% -65,923 $ -4.882M Nov 16, 2026
VOXP 0.04% 30 $ 2,068.20 Jul 31, 2026
GVLU 0.02% 831 $ 61.195K Nov 17, 2026
NPFE 0.00% 20 $ 1,378.80 Jul 31, 2026